Project description
Nanofilament therapy for aggressive lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common and aggressive form of B-cell lymphoma. Nearly 40 % of patients remain incurable despite treatment with CD20-targeted antibodies due to resistance or relapse, highlighting the need for novel therapies. The goal of the ERC-funded NanoLymphoma project is to improve DLBCL response to immunotherapy by developing an innovative therapeutic platform. The platform will be based on nanofilaments and facilitate clustering of multiple lymphoma membrane targets, including CD20, CD22 and CD37. This combination of targets is expected to induce potent cancer cell death. Importantly, it can be applied across molecularly heterogeneous B-cell lymphoma subtypes, offering a promising alternative to existing therapies.
Objective
Immunotherapy using antibodies targeting the cell surface has led to important clinical advances in patients with cancer, exemplified by CD20-antibodies that are first-line treatment in patients with B-cell lymphoma. However, diffuse large B-cell lymphoma (DLBCL), the most common and aggressive form of B-cell lymphoma worldwide, is still incurable in 40% of patients. These patients have poor prognosis due to treatment failure or relapse upon therapy with CD20-antibodies (260,000 mortalities worldwide in 2020).
Thus, there is urgent need for novel therapies to overcome resistance and enhance anti-tumor activities in patients with aggressive B-cell lymphoma.
We developed nanofilaments that can efficiently cluster multiple lymphoma membrane targets (CD20, and new targets: CD22, CD37) to induce potent tumor cytotoxicity. This new therapeutic platform (''NanoLymphoma'') represents a powerful strategy since this approach is independent from genetic cancer subtypes and is broadly applicable in molecular heterogeneous B-cell lymphoma subtypes. NanoLymphoma will evaluate and validate the technical and commercial feasibility of its new therapeutic platform to target human lymphoma cells and prepare for clinical translation to patients with DLBCL. NanoLymphoma will: 1) Show that clustering of therapeutic targets on the surface tumor cells potently induces tumor cell death, and 2) Perform market and business case analyses to ensure commercial feasibility and entry to market through Simmunext Biotherapeutics. NanoLymphoma is expected to outperform conventional anti-CD20 antibody treatment in patients with aggressive lymphoma.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- social sciences sociology demography mortality
- medical and health sciences clinical medicine oncology
- medical and health sciences basic medicine immunology immunotherapy
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.1.1 - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2022-POC2
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
6525 GA NIJMEGEN
Netherlands
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.